Humans *Adjuvants Immunologic/therapeutic use/adverse effects Administration Intravesical Neoplasm Recurrence Local/epidemiology *Urinary Bladder Neoplasms/pathology Drug Administration Schedule Bcg Cvnmi Desabastecimiento Dosis completa Dosis reducida Full dose Nmibc Reduced dose Shortage

Adjuvants Immunologic/therapeutic use Administration Intravesical Aged BCG Vaccine/therapeutic use Humans *Mycobacterium bovis Neoplasm Invasiveness Neoplasm Recurrence Local *Urinary Bladder Neoplasms

Adjuvants Immunologic/therapeutic use BCG Vaccine/therapeutic use Evidence-Based Medicine Humans Neoplasm Invasiveness Neoplasm Recurrence Local/*therapy Treatment Outcome Urinary Bladder Neoplasms/pathology/*therapy Bacillus Calmette-Guerin unresponsive Bladder preservation therapy Bladder sparing Non–muscle-invasive bladder cancer

Adjuvants Immunologic/therapeutic use Administration Intravesical Consensus Humans Neoplasm Invasiveness Neoplasm Recurrence Local/drug therapy *Urinary Bladder Neoplasms/drug therapy Bladder neoplasms Expert consensus Intravesical therapy